AR093758A1 - Inhibidores de aril lactama quinasa - Google Patents
Inhibidores de aril lactama quinasaInfo
- Publication number
- AR093758A1 AR093758A1 ARP130102716A ARP130102716A AR093758A1 AR 093758 A1 AR093758 A1 AR 093758A1 AR P130102716 A ARP130102716 A AR P130102716A AR P130102716 A ARP130102716 A AR P130102716A AR 093758 A1 AR093758 A1 AR 093758A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- haloalkyl
- 3amino
- cycloalkyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 12
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 5
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 5
- 125000001188 haloalkyl group Chemical group 0.000 abstract 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261677856P | 2012-07-31 | 2012-07-31 | |
| US13/946,344 US8901305B2 (en) | 2012-07-31 | 2013-07-19 | Aryl lactam kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR093758A1 true AR093758A1 (es) | 2015-06-24 |
Family
ID=50026068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102716A AR093758A1 (es) | 2012-07-31 | 2013-07-31 | Inhibidores de aril lactama quinasa |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8901305B2 (enExample) |
| EP (1) | EP2880032B1 (enExample) |
| JP (1) | JP2015528018A (enExample) |
| CN (1) | CN104507941A (enExample) |
| AR (1) | AR093758A1 (enExample) |
| BR (1) | BR112015001890A2 (enExample) |
| CA (1) | CA2880523A1 (enExample) |
| EA (1) | EA201590268A1 (enExample) |
| ES (1) | ES2602965T3 (enExample) |
| MX (1) | MX2015000980A (enExample) |
| TW (1) | TW201410676A (enExample) |
| WO (1) | WO2014022167A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9708337B2 (en) | 2013-02-22 | 2017-07-18 | Bristol-Myers Squibb Company | Aryl amide-based kinase inhibitors |
| US10253027B2 (en) | 2013-07-08 | 2019-04-09 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
| WO2015054358A1 (en) | 2013-10-11 | 2015-04-16 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| CN106132414A (zh) * | 2014-01-29 | 2016-11-16 | 百时美施贵宝公司 | 芳基内酰胺激酶抑制剂 |
| CA2944466C (en) | 2014-04-02 | 2020-06-09 | Bristol-Myers Squibb Company | Biaryl kinase inhibitors |
| EP3292124B1 (en) * | 2015-04-10 | 2019-05-22 | Bristol-Myers Squibb Company | 6h-isochromeno[3,4-c]pyridines and benzo[c][1,7]naphthyridin-6-(5h)-ones as adaptor associated kinase 1 (aak1) inhibitors |
| EP3356330B1 (en) * | 2015-10-01 | 2019-11-20 | Bristol-Myers Squibb Company | Biaryl kinase inhibitors |
| CN108368084B (zh) * | 2015-10-01 | 2020-10-16 | 百时美施贵宝公司 | 联芳基激酶抑制剂 |
| WO2021026349A1 (en) * | 2019-08-08 | 2021-02-11 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Combination therapy for treatment of cancer |
| CN114853664B (zh) * | 2022-06-02 | 2023-09-29 | 河南大学 | 一种钯催化条件下合成α,β-不饱和杂环己基酮类化合物的方法 |
| CN116102542A (zh) * | 2023-02-15 | 2023-05-12 | 如东众意化工有限公司 | 环丙唑醇精制母液中环丙唑醇的回收方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| BR9307570A (pt) | 1992-12-02 | 1999-05-25 | Pfizer | Diéteres de catecol como inibidores seletivos de pdeiv |
| US5709861A (en) | 1993-04-22 | 1998-01-20 | Emisphere Technologies, Inc. | Compositions for the delivery of antigens |
| AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| CA2477692A1 (en) | 2002-04-05 | 2003-10-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cyanamides useful as reversible inhibitors of cysteine proteases |
| WO2004056744A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
| US7601868B2 (en) | 2003-02-12 | 2009-10-13 | Takeda Pharmaceutical Company Limited | Amine derivative |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| CA2555287A1 (en) * | 2004-02-18 | 2005-08-25 | David Garrett Loughhead | Heterocyclic gaba-a subtype selective receptor modulators |
| WO2006012227A2 (en) | 2004-06-24 | 2006-02-02 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| CN100494167C (zh) | 2005-08-02 | 2009-06-03 | 天津大学 | 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用 |
| KR20080063833A (ko) * | 2005-12-15 | 2008-07-07 | 에프. 호프만-라 로슈 아게 | 트리시클릭 락탐 유도체, 이의 제조 및 약학적 제제로서의용도 |
| JP2007217408A (ja) | 2006-01-19 | 2007-08-30 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| CA2645031A1 (en) * | 2006-03-07 | 2007-09-13 | Bristol-Myers Squibb Company | Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors |
| US7776905B2 (en) | 2006-04-07 | 2010-08-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| WO2008022155A2 (en) | 2006-08-14 | 2008-02-21 | Wyeth | Methods of identifying agents for treating neurological disorders |
| WO2008079933A2 (en) * | 2006-12-22 | 2008-07-03 | Novartis Ag | Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections |
| CA2761298A1 (en) * | 2009-05-15 | 2010-11-18 | The University Of Kentucky Research Foundation | Treatment of mci and alzheimer's disease |
| FR2955109B1 (fr) * | 2010-01-08 | 2012-09-07 | Sanofi Aventis | Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique |
| JP5752232B2 (ja) * | 2010-03-31 | 2015-07-22 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物 |
| DK2822555T3 (en) | 2012-03-09 | 2018-02-05 | Lexicon Pharmaceuticals Inc | Inhibition of adapter-associated kinase 1 for the treatment of pain |
| NZ630719A (en) | 2012-03-09 | 2017-01-27 | Lexicon Pharmaceuticals Inc | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof |
| US8703953B2 (en) | 2012-03-09 | 2014-04-22 | Bristol-Myers Squibb Company | Aryl ether-base kinase inhibitors |
| IN2014DN07384A (enExample) | 2012-03-09 | 2015-04-24 | Lexicon Pharmaceuticals Inc |
-
2013
- 2013-07-19 US US13/946,344 patent/US8901305B2/en active Active
- 2013-07-24 CN CN201380041073.9A patent/CN104507941A/zh active Pending
- 2013-07-24 BR BR112015001890A patent/BR112015001890A2/pt not_active Application Discontinuation
- 2013-07-24 EP EP13744927.8A patent/EP2880032B1/en active Active
- 2013-07-24 EA EA201590268A patent/EA201590268A1/ru unknown
- 2013-07-24 CA CA2880523A patent/CA2880523A1/en not_active Abandoned
- 2013-07-24 MX MX2015000980A patent/MX2015000980A/es unknown
- 2013-07-24 WO PCT/US2013/051831 patent/WO2014022167A1/en not_active Ceased
- 2013-07-24 JP JP2015525460A patent/JP2015528018A/ja not_active Withdrawn
- 2013-07-24 ES ES13744927.8T patent/ES2602965T3/es active Active
- 2013-07-30 TW TW102127296A patent/TW201410676A/zh unknown
- 2013-07-31 AR ARP130102716A patent/AR093758A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2602965T3 (es) | 2017-02-23 |
| JP2015528018A (ja) | 2015-09-24 |
| EP2880032B1 (en) | 2016-10-05 |
| US20140038999A1 (en) | 2014-02-06 |
| CA2880523A1 (en) | 2014-02-06 |
| TW201410676A (zh) | 2014-03-16 |
| EP2880032A1 (en) | 2015-06-10 |
| WO2014022167A1 (en) | 2014-02-06 |
| CN104507941A (zh) | 2015-04-08 |
| EA201590268A1 (ru) | 2015-05-29 |
| BR112015001890A2 (pt) | 2017-07-04 |
| MX2015000980A (es) | 2015-04-10 |
| US8901305B2 (en) | 2014-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR100033A1 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| AR100975A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR098872A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR091279A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
| AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR110405A1 (es) | Compuestos | |
| ES2626555T3 (es) | Pyridone amides como moduladores de canales de sodio | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR095359A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR093515A1 (es) | Triazolopirazinas | |
| AR093579A1 (es) | Inhibidores de bmi-1 de pirimidina inversa sustituida | |
| AR088630A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR087909A1 (es) | Composiciones farmaceuticas | |
| AR099495A1 (es) | Derivados de amida, antagonistas de orexina | |
| AR091185A1 (es) | Derivados de 1,2,4-triazol | |
| AR093057A1 (es) | Inhibidores de la syk | |
| AR100448A1 (es) | 5-(hetero)aril-piridazinonas y su uso como herbicida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |